A Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate in the Treatment of Patients With COPD
A 12-week Double-Blind, Parallel-Group, Placebo- and Active- Controlled Trial to Evaluate the Efficacy and Safety of Formoterol Fumarate Inhalation Solution 20 Mcg in the Treatment of Patients With Chronic Obstructive Pulmonary Disease
Study Overview
Status
Status
Conditions
Conditions
Intervention / Treatment
Intervention / Treatment
Study Type
Study Type
Enrollment
Enrollment
Phase
Phase
- Phase 3
Contacts and Locations
Study Locations
-
-
Alabama
-
Jasper, Alabama, United States, 35501
- Research Site
-
-
Arizona
-
Phoenix, Arizona, United States, 85006-2666
- Research Site
-
Tuscon, Arizona, United States, 85715
- Research Site
-
-
California
-
Buena Park, California, United States, 90620
- Research Site
-
Huntington Beach, California, United States, 92647
- Research Site
-
Long Beach, California, United States, 90806
- Research Site
-
Long Beach, California, United States, 90813
- Research Site
-
Los Angeles, California, United States, 90048
- Research Site
-
San Diego, California, United States, 92120
- Research Site
-
Stockton, California, United States, 95207
- Research Site
-
-
Colorado
-
Denver, Colorado, United States, 80206
- Research Site
-
Wheat Ridge, Colorado, United States, 80033
- Research Site
-
-
Connecticut
-
Hartford, Connecticut, United States, 06105
- Research Site
-
-
Florida
-
Clearwater, Florida, United States, 33765
- Research Site
-
DeLand, Florida, United States, 32720
- Research Site
-
Tampa, Florida, United States, 33603
- Research Site
-
-
Georgia
-
Woodstock, Georgia, United States, 30189
- Research Site
-
-
Illinois
-
Hines, Illinois, United States, 60141
- Research Site
-
Normal, Illinois, United States, 61761
- Research Site
-
-
Kentucky
-
Florence, Kentucky, United States, 41042
- Research Site
-
-
Louisiana
-
New Orleans, Louisiana, United States, 70115
- Research Site
-
-
Michigan
-
Ann Arbor, Michigan, United States, 48106
- Research Site
-
-
Minnesota
-
Minneapolis, Minnesota, United States, 55402
- Research Site
-
Rochester, Minnesota, United States, 55905
- Research Site
-
-
Missouri
-
St Charles, Missouri, United States, 63301
- Research Site
-
St. Louis, Missouri, United States, 63122
- Research Site
-
-
Montana
-
Butte, Montana, United States, 59701
- Research Site
-
-
Nevada
-
Henderson, Nevada, United States, 89014
- Research Site
-
-
New Jersey
-
Cherry Hill, New Jersey, United States, 08003
- Research Site
-
Summit, New Jersey, United States, 07901
- Research Site
-
-
New Mexico
-
Albuquerque, New Mexico, United States, 87108
- Research Site
-
-
New York
-
Camillus, New York, United States, 13031
- Research Site
-
-
North Carolina
-
Charlotte, North Carolina, United States, 28207
- Research Site
-
-
Ohio
-
Cincinnati, Ohio, United States, 45241
- Research Site
-
Columbus, Ohio, United States, 43215
- Research Site
-
-
Oregon
-
Medford, Oregon, United States, 97504
- Research Site
-
Portland, Oregon, United States, 97213
- Research Site
-
-
Rhode Island
-
Cranston, Rhode Island, United States, 02920
- Research Site
-
-
South Carolina
-
Spartanburg, South Carolina, United States, 29307
- Research Site
-
-
Texas
-
Dallas, Texas, United States, 75231
- Research Site
-
San Antonio, Texas, United States, 78229
- Research Site
-
-
Virginia
-
Richmond, Virginia, United States, 23225
- Research Site
-
-
Wisconsin
-
Madison, Wisconsin, United States, 53792
- Research Site
-
Milwaukee, Wisconsin, United States, 53209
- Research Site
-
-
Participation Criteria
Eligibility Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- Medical diagnosis of COPD
- Current or prior history of cigarette smoking
Exclusion Criteria:
- Medical diagnosis of asthma
- Chest X-ray diagnostic of significant disease other than COPD
- Significant condition or disease other than COPD
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Double
What is the study measuring?
Primary Outcome Measures
Primary Outcome Measures
Outcome Measure |
|---|
|
Measure of lung function
|
Secondary Outcome Measures
Secondary Outcome Measures
Outcome Measure |
|---|
|
Change in lung function, as well as vital signs
|
|
Physical Exam results, Adverse event reporting, etc
|
Collaborators and Investigators
Sponsor
Sponsor
Publications and helpful links
General Publications
- Nelson HS, Gross NJ, Levine B, Kerwin EM, Rinehart M, Denis-Mize K; Formoterol Study Group. Cardiac safety profile of nebulized formoterol in adults with COPD: a 12-week, multicenter, randomized, double- blind, double-dummy, placebo- and active-controlled trial. Clin Ther. 2007 Oct;29(10):2167-78. doi: 10.1016/j.clinthera.2007.10.007. Erratum In: Clin Ther. 2009 Apr;31(4):920.
- Gross NJ, Nelson HS, Lapidus RJ, Dunn L, Lynn L, Rinehart M, Denis-Mize K; Formoterol Study Group. Efficacy and safety of formoterol fumarate delivered by nebulization to COPD patients. Respir Med. 2008 Feb;102(2):189-97. doi: 10.1016/j.rmed.2007.10.007.
Study record dates
Study Major Dates
Study Start
Study Start
Primary Completion (Actual)
Primary Completion
Study Completion (Actual)
Study Completion
Study Registration Dates
First Submitted
First Submitted
First Submitted That Met QC Criteria
First Submitted That Met QC Criteria
First Posted (Estimate)
First Posted
Study Record Updates
Last Update Posted (Estimate)
Last Update Posted
Last Update Submitted That Met QC Criteria
Last Update Submitted That Met QC Criteria
Last Verified
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
- Physiological Effects of Drugs
- Adrenergic Agents
- Neurotransmitter Agents
- Molecular Mechanisms of Pharmacological Action
- Autonomic Agents
- Peripheral Nervous System Agents
- Adrenergic Agonists
- Bronchodilator Agents
- Anti-Asthmatic Agents
- Respiratory System Agents
- Adrenergic beta-2 Receptor Agonists
- Adrenergic beta-Agonists
- Formoterol Fumarate
Other Study ID Numbers
Other Study ID Numbers
- 201-065
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.